Semaglutide vs Tirzepatide: Which GLP-1 Is Right for You?
Both are proven GLP-1 medications for weight loss. Compare mechanisms, results, side effects, and cost side by side.
As seen on
Quick Comparison: Semaglutide vs Tirzepatide
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Drug Class | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Brand Names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Mechanism | Targets GLP-1 receptors | Targets both GIP and GLP-1 receptors |
| Avg Weight Loss | 12–15% body weight | 15–22% body weight |
| FDA Approved For | Weight loss + Type 2 diabetes | Weight loss + Type 2 diabetes |
| Available Forms | Injectable, oral | Injectable, ODT, oral liquid |
| Monthly Cost (compounded) | From $149 | From $149 |
How Semaglutide Works
Semaglutide is a GLP-1 receptor agonist that mimics the naturally occurring GLP-1 hormone in your body. By activating GLP-1 receptors, it slows gastric emptying so you feel full longer, reduces appetite signals in the brain, and improves insulin sensitivity. These combined effects make it easier to eat less and lose weight without the constant battle against hunger.
The clinical evidence behind semaglutide is substantial. In the landmark STEP clinical trials, participants taking semaglutide 2.4 mg weekly achieved an average of 12–15% body weight reduction over 68 weeks. For someone weighing 220 lbs, that translates to roughly 26–33 lbs lost. The results were consistent across participants with and without Type 2 diabetes.
Through VivioMD, semaglutide is available as both injectable and oral compounded formulations, giving you flexibility in how you take your medication. All prescriptions are managed by licensed providers who monitor your progress and adjust dosing as needed.
Individual results may vary. Source: Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM, 2021.
How Tirzepatide Works
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. Unlike semaglutide, which targets only GLP-1 receptors, tirzepatide activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 pathways simultaneously. This dual mechanism provides enhanced appetite suppression, improved insulin secretion, and better fat metabolism compared to targeting a single pathway alone.
The clinical data for tirzepatide is compelling. In the SURMOUNT-1 trial, participants achieved an average of 15–22% body weight reduction over 72 weeks, with the highest dose (15 mg) producing up to 22.5% average weight loss. These results represent the most significant weight loss outcomes ever recorded for a pharmaceutical intervention in clinical trials.
VivioMD offers tirzepatide in multiple unique formulations: traditional injectable, oral disintegrating tablets (ODTs) for those who prefer needle-free options, and oral liquid. VivioMD also provides compound formulas including tirzepatide + B12, tirzepatide + L-carnitine + B12, and more. Learn more about tirzepatide pricing and formulations.
Individual results may vary. Source: Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM, 2022.
Key Differences Between Semaglutide and Tirzepatide
Weight Loss Efficacy
Tirzepatide demonstrates greater average weight loss in head-to-head comparisons. The SURMOUNT trials showed weight loss of up to 22.5% at the highest dose, while the STEP trials for semaglutide showed up to 14.9% body weight reduction.
The additional GIP receptor activation in tirzepatide is believed to be a key driver of the enhanced weight loss. However, individual responses vary significantly, and some patients may respond better to semaglutide depending on their unique biology and health profile.
Side Effect Profiles
Both semaglutide and tirzepatide share similar gastrointestinal side effects. The most commonly reported include nausea, diarrhea, and constipation. These effects are generally mild to moderate and tend to subside as your body adjusts during the dose titration period.
Both medications carry a boxed warning regarding thyroid C-cell tumors observed in animal studies. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use either medication. Your prescribing provider will review your full medical history before recommending a medication.
Dosing & Administration
Semaglutide is available as a once-weekly subcutaneous injection or a daily oral tablet. Dosing typically starts at 0.25 mg weekly and gradually increases to the therapeutic dose over several weeks.
Tirzepatide is administered as a once-weekly injection, with additional options including oral disintegrating tablets (ODTs) and oral liquid through compounding pharmacies. Dosing starts at 2.5 mg weekly with gradual titration upward.
Both medications follow a slow titration schedule to minimize gastrointestinal side effects. Your VivioMD provider will customize the titration plan based on your tolerance and response.
Cost Comparison
Brand-name GLP-1 medications are notoriously expensive without insurance. Ozempic and Wegovy (semaglutide) typically cost $900–1,400+/mo. Mounjaro and Zepbound (tirzepatide) run $1,000–1,200+/mo.
Through VivioMD, compounded versions of both semaglutide and tirzepatide are available for $149/mo for either medication at any dose. This includes the medication, provider consultation, ongoing monitoring, and dose adjustments. No insurance is required, and there are no hidden fees. Compare that to the alternatives with our guide to affordable Ozempic alternatives.
Available Formulations
Semaglutide is available in two forms: subcutaneous injection (most common) and oral tablet. The injectable form is taken once weekly, while the oral version (brand name Rybelsus) is taken daily.
Tirzepatide offers broader formulation options, especially through compounding. In addition to the standard injectable, VivioMD offers oral disintegrating tablets (ODTs) for needle-free dosing and an oral liquid formulation.
VivioMD also provides unique compound formulas including tirzepatide + B12, tirzepatide + L-carnitine + B12, and more. These enhanced formulations combine the weight loss benefits of tirzepatide with additional nutrients that support energy levels and metabolism.
Which Is Right for You?
Choosing between semaglutide and tirzepatide depends on several personal factors. Consider your weight loss goals — if you are looking for the maximum average weight loss, tirzepatide has the edge in clinical data. Think about your mechanism preference — some patients prefer the well-established single GLP-1 pathway of semaglutide, while others want the enhanced dual-action approach of tirzepatide.
Your formulation preference matters too. If you want a needle-free option, tirzepatide ODTs (oral disintegrating tablets) or oral liquid may be ideal. Semaglutide also has an oral option, though it requires daily dosing rather than weekly.
Ultimately, your provider will help determine the best option for your needs. During your VivioMD consultation, a licensed clinician will review your health history, weight loss goals, and preferences to recommend the right medication and formulation. Check your eligibility to get started, or learn more about how the process works.
VivioMD Offers Both Medications
Get access to semaglutide or tirzepatide from $149/mo. No insurance required, no hidden fees.
Frequently Asked Questions
Sources
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021.
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022.
- U.S. Food and Drug Administration. Approval documents for Wegovy (semaglutide 2.4 mg) for chronic weight management.
- U.S. Food and Drug Administration. Approval documents for Zepbound (tirzepatide) for chronic weight management.
Start Your GLP-1 Weight Loss Journey
Semaglutide and tirzepatide from $149/mo with licensed providers.